Free Trial

Country Will Not Resume Use Of OAZ Vaccine: VG

NORWAY

Norwegian newspaper VG reporting that the country will not resume use of the Oxford-AstraZeneca COVID-19 vaccine, after the rollout of the jab was halted amidst the concerns across Europe regarding the potential for the vaccine to cause extremely rare blood clots.

  • 27.4% of the Norwegian population have had at least one dose of a COVID-19 vaccine, placing the country above Denmark (26.4%) but below Sweden and Finland (30.0% and 35.1%) in the Nordic vaccination league table.
  • A senior panel of Norway's Institute of Public Health (FHI) recommended not using the OAZ jab, as well as the Johnson&Johnson/Janssen one-shot vaccine due to the tiny risk of blood clots.
  • Norway is already struggling with getting its migrant population to take up the vaccine, with a large proportion of the country's hospital cases from COVID-19 coming from immigrant communities. The rejection of two major vaccines is likely to slow the country's vaccination efforts further.

To read the full story

Close

Why MNI

MNI is the leading provider

of intelligence and analysis on the Global Fixed Income, Foreign Exchange and Energy markets. We use an innovative combination of real-time analysis, deep fundamental research and journalism to provide unique and actionable insights for traders and investors. Our "All signal, no noise" approach drives an intelligence service that is succinct and timely, which is highly regarded by our time constrained client base.

Our Head Office is in London with offices in Chicago, Washington and Beijing, as well as an on the ground presence in other major financial centres across the world.